# Trial of Screening for ALOA-IgG AtheroAbzyme Test

> **NCT01272986** · PHASE3 · COMPLETED · sponsor: **Omicron Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Myocardial Ischemia
- Acute Coronary Syndrome

## Interventions

- **DEVICE:** ALOA IgG-Elisa
- **DEVICE:** ALOA IgG-AtheroAbzyme

## Key facts

- **NCT ID:** NCT01272986
- **Lead sponsor:** Omicron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2011-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01272986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01272986, "Trial of Screening for ALOA-IgG AtheroAbzyme Test". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01272986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*